Description: Each 1 mL contains 150 mg of medroxyprogesterone acetate.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Duration: 3 months

  • one injection every 3 months

Dose: 150 mg every 3 months

Active Pharmaceutical Ingredient (API):
  • medroxyprogesterone acetate

Inactive material: methylparaben 1,7 mg/mL; propylparaben 0,19 mg/mL.

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Helm Pharmaceuticals, Fresenius Kabi

Project Phase: Limited Market Availability

Development Stage: Marketed

Active Development: Yes

Status Details:
  • The prequalification of Petogen by WHO is underway, and this product has recently obtained ERP, level 3, approval by UNFPA.

Additional Information

  • Helm AG:

  • Gopimohan R, et al. (2015) A clinical study assessing the efficacy of a new variant of the levonorgestrel intrauterine system for abnormal uterine bleeding. Int J Gynaecol Obstet. 129(2):114-7.

Vertical Tabs